Survival rate of liver cancer after the two academicians join hands is expected to increase significantly

On November 29, 2008, over 20 prominent domestic experts, including Wu Mengchao, an academician of the Chinese Academy of Sciences, gathered in Shanghai for a special meeting focused on the prevention of postoperative metastasis and recurrence of liver cancer under the National Special Infectious Disease Prevention and Control Project. The discussion centered around the potential of Likatin, a novel treatment approach, to significantly improve outcomes for liver cancer patients. Experts expressed optimism that this research could lead to longer progression-free survival and better overall survival rates. Liver cancer remains one of the most deadly cancers in China, ranking as the second most common tumor. Despite surgical interventions, the high rate of recurrence has not translated into improved survival for many patients. Controlling recurrence and metastasis is widely recognized as a critical factor in enhancing the success of liver cancer treatments. Since 1982, the Cell Engineering Center at the Fourth Military Medical University, led by Academician Chen Zhinan of the Chinese Academy of Engineering, has conducted extensive research. Their findings revealed that iodine-131 labeled rituximab (Likatin) can selectively target liver cancer cells. The iodine component is able to specifically destroy these malignant cells, offering a promising therapeutic option. Clinical trials have shown impressive results, with a response rate of 86.3%. In a follow-up study involving patients who had undergone liver cancer surgery, those treated with Likatin showed a significant reduction in relapse rates—30.4% lower than the control group—and a 20.6% increase in survival rates. Additionally, alpha-fetoprotein levels remained within normal ranges for a longer period, and no serious drug-related side effects were observed. Further multi-center, large-scale clinical trials are currently planned to validate these findings and explore the full potential of Likatin in preventing liver cancer recurrence. This development marks an important step forward in the fight against one of the most challenging cancers in China.

Mushrooms Extract

Mushrooms Extract Such as Shitake Mushroom Extract, Hericium Erinaceus Extract, Lions Mane Mushroom Extract, and Mushroom Extract mainly fall into the following categories:
Ganoderma lucidum extract: has immune regulation, anti-tumor, anti-oxidation, and other effects, often used in health care products and drugs.
Lentinus edodes extract: contains Lentinus edodes polysaccharide and other ingredients, has the effect of enhancing immunity, anti-tumor, etc., and has applications in food and medicine.
Ericius mushroom extract: has certain benefits on the digestive system, and can be used in functional food development.
Matsutake extract: It has antioxidant, anti-fatigue, and other effects, and is more common in high-end health products.
Main applications include:
Health care products: enhance immunity and improve health.
Medicine: Used as a pharmaceutical ingredient or as an adjunct therapeutic agent.
Functional food: Added to food to enhance nutritional value and functionality.
The main functions of mushroom extract are as follows:
Enhance immunity: can regulate the immune system, and improve the body's resistance.
Anti-tumor: Some mushroom extracts have the effect of inhibiting the growth of tumor cells.
Antioxidant: scavenging free radicals and reducing oxidative damage.
Liver protection: It has a certain protective effect on the liver.
Regulate blood sugar and lipids: helps maintain normal blood sugar and lipid levels.
Anti-fatigue: relieves body fatigue and improves energy.
Improve sleep: Helps to improve sleep quality.

Shitake Mushroom Extract,Hericium Erinaceus Extract,Lions Mane Mushroom Extract,Mushroom Extract

Shaanxi Changsheng Industrial Co., Ltd. , https://www.cncsbio.com